Update on adjuvant hormonal treatment of early breast cancer |
| |
Authors: | Juan Lao Romera Teresa de Jesús Puertolas Hernández Ignacio Peláez Fernández Teresa Sampedro Gimeno Roberto Fernández Martínez Isaura Fernández Pérez Vega Iranzo González Cruz José Juan Illarramendi Mañas Salvador Garcerá Juan Eva María Ciruelos Gil |
| |
Affiliation: | 1.Oncology Department,Hospital Miguel Servet,Zaragoza,Spain;2.Oncology Department,Hospital Cabue?es,Gijón,Spain;3.Oncology Department,Complejo Hospitalario Universitario de Vigo,Pontevedra,Spain;4.Oncology Department,Hospital General Universitario de Valencia,Valencia,Spain;5.Oncology Department,Hospital de Navarra,Pamplona,Spain;6.Oncology Department,Hospital Universitario de La Ribera,Alzira,Spain;7.Oncology Department,Hospital Universitario 12 de Octubre,Madrid,Spain |
| |
Abstract: | Clinical trials conducted over the last two decades have demonstrated that 5 years of treatment with tamoxifen (TAM) after local treatment in postmenopausal patients with positive hormone receptor early breast cancer improves disease-free survival and overall survival. More recently, aromatase inhibitors (AI) have been tested in several randomized clinical trials in this setting. The studies have tested either AI versus TAM or different sequential approaches combining the two agents. While the most effective strategy remains to be determined, overall, incorporation of AI resulted in better disease-free survival, particularly in the worst-prognosis subgroup of patients. In addition, long-term treatment with AI was, in general, well tolerated. However, mature results are needed in order to be able to assess the effect in overall survival. The authors of this supplement paper include the key points of roundtable presentations and discussions of hormonal therapy in breast cancer by topic. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|